| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT01525225 Details | 2015-06-22 Interventional | 1 | 4 | Metformin Saxagliptin Diabetes Mellit… Diabetes Mellit… Type 2 Diabetes… | Release of Post Marketing Requirement for this study. Terminated November 2013. Due to the small number of participants (2), the primary endpoints, pharmacokinetic parameters, were not calculated. | |||
| NCT01222143 Details | 2015-06-22 Interventional | 1/2 | 12 | Nilotinib Leukemia Leukemia, Myelo… Leukemia, Myelo… Acute Myeloid L… | - - | |||
| NCT02429882 2014-003701-15 Details | 2015-06-19 Interventional | 2 | 0 | Brodalumab Axial Spondyloa… Spondylarthriti… Spondylitis | Per Amgen's decision to discontinue co-development and co-commercialization of brodalumab,
study is being cancelled/closed. - | |||
| NCT02083276 2013-002379-17 Details | 2015-06-19 Interventional | 2 | 20 | Amdinocillin Pi… Chlamydia Infec… Communicable Di… Infections Urethritis Chlamydia Trach… Chlamydial Uret… | Treatment failure on study medication observed - | |||
| NCT01655212 2011-005378-44 Details | 2015-06-18 Interventional | 3 | 2 | Valganciclovir Cytomegalovirus… Deafness Hearing Loss Hearing Loss, S… Congenital Cyto… Sensorineural H… | 1 Indication for further investigations (brain ultrasound). 2 Change of study design to
efficacy study with historical control group. - | |||
| NCT01467505 Details | 2015-06-18 Interventional | 2 | 61 | Immunosuppressi… Interferon alph… Interferon-alph… Interferons Peginterferon a… Ribavirin Hepatitis Hepatitis C | The study was terminated early by the sponsor on 13 January 2014 due to a decision to modify
the drug development plan. It was decided by Sponsor on 13 January 2014 to terminate the study early at the primary efficacy endpoint (SVR12) as part of a decision to modify the drug development plan. Eligible participants completed virologic follow-up after termination. | |||
| NCT01356992 Details | 2015-06-18 Interventional | 3 | 62 | Enoxaparin Acute Coronary … Angina, Unstabl… Infarction Myocardial Infa… Non ST Segment … Unstable Angina | Change in strategy regarding the product by the company - | |||
| NCT02240602 Details | 2015-06-16 Interventional | 3 | 0 | Oxycodone Pain, Postopera… Pain | Lack of internal resources - | |||
| NCT00703690 Details | 2015-06-12 Interventional | 2 | 436 | Fenofibrate Dyslipidemias Metabolic Syndr… Syndrome Metabolic X Syn… | - - | |||
| NCT00543361 Details | 2015-06-12 Interventional | 3 | 382 | Metformin Diabetes Mellit… | - - | |||
| NCT00396487 2006-002957-56 Details | 2015-06-11 Interventional | 3 | 1 | Capecitabine Fluorouracil Irinotecan Colorectal Neop… Metastatic Colo… | Only one patient included as per Feb. 4, 2008. - | |||
| NCT01720056 Details | 2015-06-10 Interventional | 4 | 14 | Triamcinolone A… Verapamil Keloid Recurrence Keloid Scars | Objective of study achieved after interim analysis. - | |||
| NCT01459913 Details | 2015-06-10 Interventional | 3 | 239 | Interferon alph… Interferon-alph… Interferons Peginterferon a… Ribavirin Hepatitis Hepatitis C Hepatitis C, Ch… | The study was terminated early by the sponsor on 13 January 2014 due to a decision to modify
the drug development plan. The study was terminated early at the primary efficacy endpoint (SVR12), by the sponsor on 13 January 2014 due to a decision to modify the drug development plan. | |||
| NCT00875875 Details | 2015-06-10 Interventional | 4 | 0 | Rifaximin Diarrhea Dysentery Travelers' Diar… | No study population in Mexico (H1N1). Study withdrawn from IRB consideration. - | |||
| NCT00718809 Details | 2015-06-10 Interventional | 2 | 21 | Saracatinib Carcinoma Thymoma Thymus Neoplasm… Invasive Thymom… Recurrent Thymo… Stage III Thymo… Stage IVA Thymo… Stage IVB Thymo… | - - | |||
| NCT02120118 Details | 2015-06-09 Interventional | 2 | 0 | Docetaxel Hyperthermia Solid Tumors | Taiwan FDA asked for seperating this protocol into one disease site per protocol. - | |||
| NCT01080248 Details | 2015-06-09 Interventional | 2 | 2 | Gemcitabine Pancreatic Neop… Pancreatic Canc… | Closed due to delay by GSK - | |||
| NCT00800150 Details | 2015-06-08 Interventional | 1 | 6 | Fludarabine Fludarabine pho… Melphalan Leukemia Lymphoma Multiple Myelom… Myelodysplastic… Myelodysplastic… Myeloproliferat… Neoplasms Neoplasms, Plas… Plasmacytoma Preleukemia Syndrome Chronic Myelopr… Multiple Myelom… Myelodysplastic… | Protocol objective could not be met. A new study with amended eligibility criteria will be
developed. - | |||
| NCT00019864 NCT00001821 Details | 2015-06-08 Interventional | 2 | - | Calcium Dexrazoxane Doxorubicin Leucovorin Levoleucovorin Liposomal doxor… Methotrexate Razoxane Cardiotoxicity Osteosarcoma Cardiac Toxicit… Sarcoma | - - | |||
| NCT00005777 Details | 2015-06-08 Interventional | 3 | [2 Refs] | 220 | Dexamethasone Birth Weight Bronchopulmonar… Lung Diseases Premature Birth Respiratory Dis… Respiratory Dis… Infant, Low Bir… Infant, Newborn Infant, Prematu… Infant, Small f… | The trial was halted because of unanticipated nonrespiratory adverse events related to
dexamethasone therapy. - |